A high throughput, in vitro screening system for treatments of oral mucositis in cancer
用于治疗癌症口腔粘膜炎的高通量体外筛选系统
基本信息
- 批准号:10041746
- 负责人:
- 金额:$ 14.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAffectAlprostadilAnti-Inflammatory AgentsAntibodiesApoptosisBacterial InfectionsBiologicalBiological AssayBiopsyCancer PatientCarbohydratesCell Culture TechniquesCell LineCell SurvivalCell physiologyCellsCellular MorphologyChemotherapy and/or radiationChemotherapy-Oncologic ProcedureCisplatinClinicalClinical TrialsConflict (Psychology)DevelopmentDevicesDiffusionDoseDose-LimitingDoxorubicinEatingEndothelial CellsEndotheliumEpithelialEpitheliumEtiologyEvaluationEventExposure toFDA approvedFibroblastsFluorescenceFluorouracilFundingFutureGene Expression ProfileGenetic TranscriptionGingivaGoalsHealthHourHumanImmuneImpairmentIn SituIn Situ Nick-End LabelingIn VitroInterleukin-6InterventionKnowledgeLabelLeadMalignant NeoplasmsMeasuresMesenchymalMethotrexateModelingMolecularMonoclonal AntibodiesMucositisMucous MembraneNational Institute of Dental and Craniofacial ResearchNeutropeniaNutrientOralOral healthPainPatient riskPatientsPatternPharmaceutical PreparationsPharmacotherapyPreclinical TestingProteomicsRadiation therapySodium ChlorideStainsStructureSymptomsSystemTestingTetrazoliumTissue MicroarrayTissuesTranslatingTranslationsUlcerUnited StatesUnited States National Institutes of HealthVascular Endothelial Cellbasecancer therapycell typechemotherapycytokinedrug candidateexperimental studyfluorescein isothiocyanate dextranhigh riskhigh throughput screeningindividual responseinnovationkeratinocytekeratinocyte growth factornoveloral bacteriaoral mucositispersonalized medicinepre-clinicalprecision medicineresponsescreeningside effectspatiotemporalsuccesstranscriptometranscriptome sequencingtreatment effecttreatment strategy
项目摘要
7. Project Summary/Abstract
Oral mucositis is a painful, treatment-modifying side effect of cancer therapy that affects roughly 250,000 cancer
patients annually in the United States. Currently, the only FDA-approved drug to treat oral mucositis, palifermin,
is in only about 4% of clinical cases. The long-term objectives of this project are to elucidate molecular
mechanisms of damage initiation in mucositis, including RNA expression signatures, and the timing of cell-
specific events, and also to facilitate the discovery and translation of new anti-mucositis drug candidates. This
project is expected to directly support a future, personalized medicine approach for treating oral mucositis in
cancer patients. The initiation of mucositis is thought to involve the innate immune and damage response of
structural gingival cells, beginning with sub-epithelial endothelial and mesenchymal cells, and evolving toward
damage to gingival keratinocytes and epithelial ulceration. Therefore, development of a gingiva-on-a-chip,
involving culture of the cells implicated in the initiation of mucositis, is expected to support these objectives.
This proposal aims to (1) determine initiation of gingival disruption on a chip exposed to cancer therapies, and
(2) determine responses of the gingiva-on-a-chip to putative drug treatments for oral mucositis. Achievement of
Aim 1 will involve establishing a baseline of cell function and molecular expression in a tri-culture chip featuring
human gingival keratinocyte, fibroblast, and microvascular endothelial cell lines. Viability, apoptosis, proliferation,
transcriptional programming, and cytokine secretion of each cell type on the chip will be determined using
(immuno)fluorescence assays on cells, tetrazolium salt and cytokine antibody array assays on conditioned
nutrient media, and whole transcriptome RNA sequencing. Responses to four doses of four chemotherapy
agents implicated in oral mucositis will be assessed and compared to baseline in the chip and in wellplate
monoculture using the same assays. Achievement of Aim 2 will involve testing of four anti-mucositis therapies
on the chip, for cultures exposed to one chemotherapy agent at a dose found to elicit hallmarks of mucositis,
using the same assays as in Aim 1. Gingival barrier function will be assessed in all experiments by tracking
fluorescently labeled oral bacterium and carbohydrate molecules of known size across the cell layers.
The health-relatedness of this proposal lies in directly impacting oral health and supporting development
of precision medicine approaches through knowledge of oral mucositis and the effects of treatments on a chip.
The proposed system would serve as a model of the initiation of mucositis in human gingiva and could test novel
anti-mucositis drug candidates in parallel with pre-clinical tests. Such knowledge would potentially lead to more
successes at the level of clinical trials targeting oral mucositis interventions. Translated to primary culture of
gingival biopsies of cancer patients, the chip-based platform would support personalized modeling and mitigation
of mucositis by pairing cancer therapies with the best anti-mucositis therapy, determined on the chip.
7.项目摘要/摘要
口腔粘膜炎是癌症治疗的一种痛苦的、影响治疗的副作用,影响大约250,000例癌症
在美国每年都有病人。目前,FDA批准的唯一治疗口腔粘膜炎的药物,帕利福明,
仅占临床病例的4%左右。这个项目的长期目标是阐明分子
粘膜炎的损伤起始机制,包括RNA表达特征,以及细胞-
此外,还有助于发现和翻译新的抗粘膜炎候选药物。这
该项目预计将直接支持未来的个性化医学方法,用于治疗口腔粘膜炎
癌症患者。粘膜炎的启动被认为涉及到先天免疫和损伤反应
结构性牙龈细胞,始于上皮下层内皮细胞和间充质细胞,并向
对牙周角质形成细胞和上皮溃烂的损害。因此,开发一种芯片上的牙床,
包括与粘膜炎的启动有关的细胞培养,预计将支持这些目标。
这项提议旨在(1)在暴露于癌症治疗的芯片上确定牙龈破裂的开始,以及
(2)测定牙周膜对治疗口腔粘膜炎药物的反应。取得的成就
目标1将涉及在三种培养芯片中建立细胞功能和分子表达的基线,包括
人牙周角质形成细胞、成纤维细胞和微血管内皮细胞系。生存、凋亡、增殖、
芯片上每种细胞类型的转录编程和细胞因子分泌将使用以下方法确定
细胞(免疫)荧光检测、四唑盐和细胞因子抗体阵列检测
营养培养基及全转录组RNA测序。对四种不同剂量化疗的反应
涉及口腔粘膜炎的药物将在芯片和井板中进行评估并与基线进行比较
使用相同的分析方法进行单一培养。实现目标2将涉及四种抗粘膜炎疗法的测试
在芯片上,对于暴露在一种化疗药物剂量下的培养物,发现会引发粘膜炎的特征,
使用与目标1相同的分析方法。将在所有实验中通过跟踪评估牙龈屏障功能
细胞层上已知大小的荧光标记口腔细菌和碳水化合物分子。
这项提议与健康的相关性在于直接影响口腔健康和支持发展
通过了解口腔粘膜炎和芯片上的治疗效果,实现精确医学方法的研究。
建议的系统将作为人类牙龈粘膜炎的启动模型,并可以测试新的
抗粘膜炎药物候选与临床前试验平行进行。这样的知识可能会导致更多
针对口腔粘膜炎干预措施的临床试验取得成功。翻译成的主要文化
癌症患者的牙龈活检,基于芯片的平台将支持个性化建模和缓解
通过将癌症治疗与芯片上确定的最好的抗粘膜炎治疗相结合,可以减少粘膜炎的风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher B Raub其他文献
Christopher B Raub的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher B Raub', 18)}}的其他基金
A high throughput, in vitro screening system for treatments of oral mucositis in cancer
用于治疗癌症口腔粘膜炎的高通量体外筛选系统
- 批准号:
10251272 - 财政年份:2020
- 资助金额:
$ 14.66万 - 项目类别:
A dual-modality quantitative phase and polarized light microscope to assess cell motility and extracellular matrix remodeling during invasion
双模态定量相和偏光显微镜评估侵袭过程中的细胞运动和细胞外基质重塑
- 批准号:
9924599 - 财政年份:2019
- 资助金额:
$ 14.66万 - 项目类别:
Controlling chondrocyte matrix degradation and repair in 3-D culture.
控制 3D 培养中的软骨细胞基质降解和修复。
- 批准号:
7807636 - 财政年份:2010
- 资助金额:
$ 14.66万 - 项目类别:
Controlling chondrocyte matrix degradation and repair in 3-D culture.
控制 3D 培养中的软骨细胞基质降解和修复。
- 批准号:
8035903 - 财政年份:2010
- 资助金额:
$ 14.66万 - 项目类别:
Controlling chondrocyte matrix degradation and repair in 3-D culture.
控制 3D 培养中的软骨细胞基质降解和修复。
- 批准号:
8213730 - 财政年份:2010
- 资助金额:
$ 14.66万 - 项目类别:
Multiphoton Imaging and Rheology of Fibrosis Models
纤维化模型的多光子成像和流变学
- 批准号:
7407804 - 财政年份:2007
- 资助金额:
$ 14.66万 - 项目类别:
Multiphoton Imaging and Rheology of Fibrosis Models
纤维化模型的多光子成像和流变学
- 批准号:
7496521 - 财政年份:2007
- 资助金额:
$ 14.66万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 14.66万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 14.66万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 14.66万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 14.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




